Arvinas Inc.
5 Science Park
395 Winchester Ave
New Haven
Connecticut
06511
United States
Website: https://www.arvinas.com/
About Arvinas Inc.
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.
QUALITY BENEFITS
Designed with health and wellness in mind, employees and their families are eligible for:
- Medical, dental, and vision options, including a generous company contribution into an HSA
- Paid maternity and paternity leave
- FSA, HSA, Healthcare, and Dependent Care accounts
- Company provided life insurance and short/long-term disability coverage
- Additional voluntary benefits including critical illness, hospital care and more
COMPENSATION & EQUITY
Central to our organization is attracting, retaining and engaging the best and brightest by sharing in the success of our organization:
- Competitive salaries and an annual incentive program
- 401K matching program with immediate vesting
- Eligibility for long-term equity incentives upon hire and annually
TIME OFF
We believe it’s important to relax, unwind and enjoy life’s moments:
- Paid vacation
- A year-end office closure
- Observed company holidays
- Paid sabbatical upon 5 years’ tenure
We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. We take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.
Working at Arvinas
109 articles about Arvinas Inc.
-
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
5/8/2023
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.
-
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/5/2023
Arvinas, Inc. today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
5/3/2023
Arvinas, Inc. announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m.
-
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
5/2/2023
Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas' vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.
-
Arvinas to Present at Stifel Targeted Oncology Day
4/21/2023
Arvinas, Inc. announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET.
-
Arvinas to Participate in Upcoming March 2023 Investor Conferences
2/27/2023
Arvinas, Inc. announced that management will participate in two upcoming investor conferences.
-
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2/23/2023
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
-
Arvinas to Participate in Upcoming Investor Conferences - February 06, 2023
2/6/2023
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that management will participate in three upcoming investor conferences.
-
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Arvinas, Inc. today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT in San Francisco, Calif.
-
Late Monday, Arvinas Inc. was forced to divulge the contents of its upcoming breast cancer data presentation, slated for the 2022 San Antonio Breast Cancer Symposium (“SABCS”).
-
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
11/22/2022
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer.
-
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Arvinas to Present at Upcoming Conferences - November 01, 2022
11/1/2022
Arvinas, Inc. announced that it will participate in two upcoming conferences:
-
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
10/27/2022
Arvinas, Inc. announced Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute/Harvard Medical School as the winner of the 2022 Arvinas Early Career Research Award last night at the 5th Annual Targeted Protein Degradation Summit in Boston.
-
Arvinas Gives Back to Local Greater New Haven Community
9/30/2022
Arvinas, Inc. announced that nearly 200 employees participated in the Company’s inaugural “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area.
-
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
-
Arvinas Announces Changes to its Board of Directors
8/18/2022
Arvinas, Inc. announced that Liam Ratcliffe, M.D., Ph.D. has stepped down from the company’s Board and John Young has been appointed to join.
-
Arvinas Appoints John Northcott as Chief Commercial Officer
8/1/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO).
-
Foundation Medicine Announces Strategic Collaboration with Arvinas
6/5/2022
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne®Liquid CDx as a companion diagnostic for use with Arvinas’ bavdegalutamide, an investigational novel PROTAC® protein degrader targeting the androgen receptor.
-
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
6/2/2022
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif.